FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

Inclusion criteria

• ✓. Adult (\>18 years) male and female patients
• ✓. Females of childbearing potential and males and their female partner(s) of childbearing potential must use two acceptable forms of contraception, one being a barrier method, during the study and also for 31 weeks (females) or 18 weeks (males) after last study drug administration.
• ✓. Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations
• ✓. The patient has read, understood, and signed the written informed consent form(s)
• ✓. Advanced or metastatic solid tumor that is refractory to standard treatment, for which no standard treatment is available, or it is contraindicated, or the patient refuses standard therapy:
• ✓. Laboratory values at initial screening and also within three days prior to dosing of \[Lu-177\]-PNT6555:
• ✓. Platelets greater than 120,000/ mm\^3 at dosing. Transfusions allowed, but not for first dose
• ✓. Neutrophils greater than 1500cells/mm\^3

Exclusion criteria